This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.
Have objective, documented damage to the retina or optic nerve unlikely to improve OR
Have objective, documented damage to the retina or optic nerve that is progressive AND have less than or equal to 20/30 best corrected central visual acuity in one or both eyes AND/OR an abnormal visual field in one or both eyes.
Be at least 3 months post-surgical treatment intended to treat any ophthalmologic disease and stable.
If under current medical therapy ( pharmacologic treatment) for a retinal or optic nerve disease be considered stable on that treatment and unlikely to have visual function improvement ( for example, glaucoma with intraocular pressure stable on topical medications but visual field damage ).
Patients who are not capable of an adequate ophthalmologic examination or evaluation to document the pathology.
Patients who are not capable or not willing to undergo follow up eye exams with the principle investigator or their ophthalmologist or optometrist as outlined in the protocol.
Patients who are not capable of providing informed consent.
Patients who may be at significant risk to general health or to the eyes and visual function should they undergo the procedure.
MD Stem Cells
Lead sponsor